Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy

Authors: Uy, Geoffrey L., Pullarkat, Vinod, Baratam, Praneeth, Stuart, Robert K., Walter, Roland B., Winer, Eric S., Wang, Qi, Faderl, Stefan, Chakravarthy, Divya, Menno, Diane, Cheung, Ronald S., Lin, Tara L.

Source: In Blood Advances 24 December 2024 8(24):6248-6256

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Authors: Lancet, Jeffrey E ^*, Uy, Geoffrey L, Newell, Laura F, Lin, Tara L, Ritchie, Ellen K, Stuart, Robert K, Strickland, Stephen A, Hogge, Donna, Solomon, Scott R, Bixby, Dale L, Kolitz, Jonathan E, Schiller, Gary J, Wieduwilt, Matthew J, Ryan, Daniel H, Faderl, Stefan, Cortes, Jorge E

Source: In The Lancet Haematology July 2021 8(7):e481-e491

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Authors: Lin, Tara L. ^*, Rizzieri, David A., Ryan, Daniel H., Schiller, Gary J., Kolitz, Jonathan E., Uy, Geoffrey L., Hogge, Donna E., Solomon, Scott R., Wieduwilt, Matthew J., Ryan, Robert J., Faderl, Stefan, Cortes, Jorge E., Lancet, Jeffrey E.

Source: In Blood Advances 23 March 2021 5(6):1719-1728

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

Authors: Jacoby, Meagan A., Finn, Laura, Emadi, Ashkan, Saba, Nakhle S., Powell, Bayard L., Seiter, Karen, Garcia, Rosella, Faderl, Stefan, Male, Heather J.

Source: Leukemia & lymphoma. 62(10):2539-2542

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132329098.0x000001&indx=1&recIds=ETOCvdc_100132329098.0x000001

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Authors: Lee, Je-Hwan ^*, Faderl, Stefan ^*, Pagel, John M., Jung, Chul Won, Yoon, Sung-Soo, Pardanani, Animesh D., Becker, Pamela S., Lee, Howard, Choi, Jeongeun, Lee, Kyoungjune, Kim, Minkyoung, Cortes, Jorge E.

Source: In Blood Advances 12 May 2020 4(9):2032-2043

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Authors: Savona, Michael R, Odenike, Olatoyosi, Amrein, Philip C, Steensma, David P, DeZern, Amy E, Michaelis, Laura C, Faderl, Stefan, Harb, Wael, Kantarjian, Hagop, Lowder, James, Oganesian, Aram, Azab, Mohammad, Garcia-Manero, Guillermo

Source: In The Lancet Haematology April 2019 6(4):e194-e203

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Authors: Fathi, Amir T., Erba, Harry P., Lancet, Jeffrey E., Stein, Eytan M., Ravandi, Farhad, Faderl, Stefan, Walter, Roland B., Advani, Anjali S., DeAngelo, Daniel J., Kovacsovics, Tibor J., Jillella, Anand, Bixby, Dale, Levy, Moshe Y., O'Meara, Megan M., Ho, Phoenix A., Voellinger, Jenna, Stein, Anthony S.

Source: In Blood 13 September 2018 132(11):1125-1133

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Authors: Uy, Geoffrey L., Newell, Laura F., Goldberg, Stuart L, Wieduwilt, Matthew J., Ryan, Robert J., Faderl, Stefan, Lin, Tara L.

Source: Transplantation and Cellular Therapy. 27(S):S58-S60

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134294563.0x000001&indx=1&recIds=ETOCvdc_100134294563.0x000001

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Authors: Stein, Eytan M., Walter, Roland B., Erba, Harry P., Fathi, Amir T., Advani, Anjali S., Lancet, Jeffrey E., Ravandi, Farhad, Kovacsovics, Tibor, DeAngelo, Daniel J., Bixby, Dale, Faderl, Stefan, Jillella, Anand P., Ho, Phoenix A., O'Meara, Megan M., Zhao, Baiteng, Biddle-Snead, Charles, Stein, Anthony S.

Source: In Blood 25 January 2018 131(4):387-396

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

Authors: Abaza, Yasmin, Kantarjian, Hagop, Garcia-Manero, Guillermo, Estey, Elihu, Borthakur, Gautam, Jabbour, Elias, Faderl, Stefan, O'Brien, Susan, Wierda, William, Pierce, Sherry, Brandt, Mark, McCue, Deborah, Luthra, Rajyalakshmi, Patel, Keyur, Kornblau, Steven, Kadia, Tapan, Daver, Naval, DiNardo, Courtney, Jain, Nitin, Verstovsek, Srdan, Ferrajoli, Alessandra, Andreeff, Michael, Konopleva, Marina, Estrov, Zeev, Foudray, Maria, McCue, David, Cortes, Jorge, Ravandi, Farhad

Source: In Blood 9 March 2017 129(10):1275-1283

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

Authors: Solomon, Scott R., Powell, Bayard L., Koprivnikar, Jamie, Lai, Catherine, Male, Heather, Michaelis, Laura C., Newell, Laura F., Sanford, David, Jenkins, Jack, Zelaya, Amy, Coppola, Sheryl, Faderl, Stefan, Walter, Roland B.

Source: Cancers; Mar2024, Vol. 16 Issue 5, p915, 11p

Subject Terms: THERAPEUTIC use of antineoplastic agents, PHARMACEUTICAL arithmetic, HEMATOLOGIC malignancies, PATIENT safety, CREATININE, CLINICAL trials, ANTINEOPLASTIC agents, BLOOD collection, DESCRIPTIVE statistics, CYTARABINE, KIDNEY diseases, COMPARATIVE studies, URINE collection & preservation, DAUNOMYCIN

Geographic Terms: UNITED States

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Authors: Jabbour, Elias, Kantarjian, Hagop, Ravandi, Farhad, Thomas, Deborah, Huang, Xuelin, Faderl, Stefan, Pemmaraju, Naveen, Daver, Naval, Garcia-Manero, Guillermo, Sasaki, Koji, Cortes, Jorge, Garris, Rebecca, Yin, C Cameron, Khoury, Joseph D, Jorgensen, Jeffrey, Estrov, Zeev, Bohannan, Zachary, Konopleva, Marina, Kadia, Tapan, Jain, Nitin, DiNardo, Courtney, Wierda, William, Jeanis, Vicky, O'Brien, Susan

Source: In The Lancet Oncology November 2015 16(15):1547-1555

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Authors: Quintás-Cardama, Alfonso, Daver, Naval, Kim, Hawk, Dinardo, Courtney, Jabbour, Elias, Kadia, Tapan, Borthakur, Gautam, Pierce, Sherry, Shan, Jianqin, Cardenas-Turanzas, Marylou, Cortes, Jorge, Ravandi, Farhad, Wierda, William, Estrov, Zeev, Faderl, Stefan, Wei, Yue, Kantarjian, Hagop, Garcia-Manero, Guillermo

Source: In Clinical Lymphoma Myeloma and Leukemia October 2014 14(5):401-410

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Authors: Strati, Paolo, Keating, Michael J., O’Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G. ^*

Source: In Blood 12 June 2014 123(24):3727-3732

Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Authors: Faderl, Stefan, Balakrishnan, Kumudha, Thomas, Deborah A., Ravandi, Farhad, Borthakur, Gautam, Burger, Jan, Ferrajoli, Alessandra, Cortes, Jorge, O'Brien, Susan, Kadia, Tapan, Feliu, Jennie, Plunkett, William, Gandhi, Varsha, Kantarjian, Hagop M.

Source: In Clinical Lymphoma Myeloma and Leukemia June 2014 14(3):231-238

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

Authors: Rozovski, Uri, Harris, David M., Li, Ping, Liu, Zhiming, Wu, Ji Yuan, Grgurevic, Srdana, Faderl, Stefan, Ferrajoli, Alessandra, Wierda, William G., Martinez, Matthew

Source: Journal of immunology. 196(10):4400-4409

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN606080382&indx=1&recIds=ETOCRN606080382

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

Authors: Sampath, Deepa, Malik, Asifa, Plunkett, William, Nowak, Billie, Williams, Betsy, Burton, Michelle, Verstovsek, Srdan, Faderl, Stefan, Garcia-Manero, Guillermo, List, Alan F., Sebti, Said, Kantarjian, Hagop M., Ravandi, Farhad, Lancet, Jeffrey E.

Source: In Leukemia Research November 2013 37(11):1461-1467

Expectations of Serious Adverse Events at the End of Life of Patients With Acute Myeloid Leukemia Who Receive Salvage Therapy

Authors: Cardenas-Turanzas, Marylou, Ravandi-Kashani, Farhad, Cortes, Jorge E., Jabbour, Elias, Faderl, Stefan, Pierce, Sherry A., Kantarjian, Hagop

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2013 13(5):579-583

Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia

Authors: Strati, Paolo, Daver, Naval, Ravandi, Farhad, Pemmaraju, Naveen, Pierce, Sherry, Garcia-Manero, Guillermo, Nazha, Aziz, Kadia, Tapan, Jabbour, Elias, Borthakur, Gautam, Faderl, Stefan, Quintas-Cardama, Alfonso, Kantarjian, Hagop, Cortes, Jorge

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2013 13 Supplement 2:S276-S281

Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Authors: Ravandi, Farhad ^*, Jorgensen, Jeffrey L., Thomas, Deborah A., O'Brien, Susan, Garris, Rebecca, Faderl, Stefan, Huang, Xuelin, Wen, Sijin, Burger, Jan A., Ferrajoli, Alessandra, Kebriaei, Partow, Champlin, Richard E., Estrov, Zeev, Challagundla, Pramoda, Wang, Sa A., Luthra, Rajyalakshmi, Cortes, Jorge E., Kantarjian, Hagop M.

Source: In Blood 15 August 2013 122(7):1214-1221